S Korean firm specialising in life science technology to set ground in Qatar
A South Korean company specialising in genome editing has announced plans to initiate the development of treatments for genetic diseases in Qatar with local collaboration.
“Qatar stands out in the Gulf region as a centre for medical excellence, having global educational institutions providing research and development (R&D), training, and education for the future pioneers in the field of medicine and science.
“We at G+FLAS have recognised this and have initiated our goal of establishing a centre in Doha to share our R&D experience in genome editing, CRISPR PLUS technology,” the company said in a statement.
G+FLAS, which is based in South Korea, was founded in 2014 by its CEO, Dr Sunghwa Choe, and specialises in CRISPR-Cas genome editing technology and applicational technology development; product development and production of biomedicine, and anti-cancer drugs, among others; plant-derived pharmaceuticals; genetic disease treatment; precision targeted therapy; CRISPR Cancerase; non-GMO; novel seed for arid lands; and ‘future food’.
“Through the efforts of Mr Dae Ho Kim, G+FLAS Life Sciences will be establishing a base in Qatar to carry forward its R&D, in collaboration with the local medical and agro-related research industry.
“Mr Kim comes with over 40 years of Middle East experience and will be heading the locally-established company. Already, patents for Qatar have been filed and several more are in the process. G+FLAS Life Sciences would be established in the country as soon as Mr Kim and his team could visit Qatar,” the statement explained.
Only recently, HE Qatar’s ambassador to the Republic of Korea Mohamed bin Ahmad al-Hayki visited the G+FLAS headquarters in Seoul to gain insight on the technology and understand the progress achieved and what is in the pipeline, Kim told Gulf Times Monday.
“Currently we are working on treatments and vaccines for breast cancer, colorectal cancer, lung cancer, Fabry disease,